Chronic hepatitis C treatment: a systematic review

Aishah Mohammed, Alenezi; Abdulaziz Hassan Mohammed, Al Fakih; Sultan Mohammed, Al Afif; Abdulkarem Mohammed, Al Afif; Bashayer Abbas, Habib; Mooj Abdullah, Alghofaili; Shaykhah Ali, Almalki; Shahad Dhafer, Adraj; Mada Khaled, Arfaj; Waad Musayid, Alsadi; Lama Hamed, Almazroei; Amjad Meshal, Allhyani; Hanof Abdulrhman, Bakri; Bandar Aedh, Alyami; Ola Ali, Alsaihati; Zahra Issa A., Al Ali; Abdulrahman Salem D., Altalhi; Abdualrhman Ali, Al Amri; Arwa Ibrahim Y., Ramel

Aishah Mohammed, Alenezi; Abdulaziz Hassan Mohammed, Al Fakih; Sultan Mohammed, Al Afif; Abdulkarem Mohammed, Al Afif; Bashayer Abbas, Habib; Mooj Abdullah, Alghofaili; Shaykhah Ali, Almalki; Shahad Dhafer, Adraj; Mada Khaled, Arfaj; Waad Musayid, Alsadi; Lama Hamed, Almazroei; Amjad Meshal, Allhyani; Hanof Abdulrhman, Bakri; Bandar Aedh, Alyami; Ola Ali, Alsaihati; Zahra Issa A., Al Ali; Abdulrahman Salem D., Altalhi; Abdualrhman Ali, Al Amri; Arwa Ibrahim Y., Ramel.

Egyptian Journal of Hospital Medicine [The]. 2017; 67 (1): 305-313

in English | IMEMR | ID: emr-189181

ABSTRACT

ABSTRACT

Background:

Chronic hepatitis C [CHC] infection affects almost 3% of the global population and can lead to cirrhosis, liver failure, and hepatocellular carcinoma in a significant number of those infected. Thus, there is a compelling need to develop and introduce new therapeutics with a direct-acting antiviral effect in order to target various stages of the HCV lifecycle for HCV eradication without concomitant interferon

Subject(s)

Humans; Hepacivirus; Genotype; Simeprevir/therapeutic use; Sofosbuvir/therapeutic use; Interferons/therapeutic use; Ribavirin/therapeutic use

Search on Google

XML

Index: IMEMR (Eastern Mediterranean) Main subject: Ribavirin / Interferons / Hepacivirus / Simeprevir / Sofosbuvir / Genotype Type of study: Systematic reviews Limits: Humans Language: English Journal: Egypt. J. Hosp. Med. Year: 2017

Similar

MEDLINE

LILACS

LIS

Search on Google

XML